Device Trial Radar · NCT07227805
Evaluation of the Safety and Performance of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in People Living With Diabetes (NEXUS)
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
116
Planned (sponsor's estimate)
Start
Jul 19, 2026
Primary completion
Mar 17, 2027
Study completion Mar 17, 2027
Sponsor
- Lead sponsor
- Medtronic MiniMed, Inc.Public (MDT)
- Sponsor type
- Industry
- First posted
- Nov 13, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will demonstrate the safety and performance of the Novel Medtronic Experimental Automated Insulin Delivery system named MiniMed™ NMX8 system in people living with insulin-requiring diabetes in comparison with the MiniMed™ 780G system.
Conditions
- Diabetes (Insulin-requiring, Type 1 or Type 2)
Interventions
NMX8Device
Subjects will start using the MiniMed™ NMX8 system for 12 weeks
780GDevice
Subjects will continue to use the MiniMed™ 780G for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary EndpointTime frame: During the 12-week study phase
Locations
9 sites in 4 countries. Site status is shown where the registry gives one.
Universitair Ziekenhuis Antwerpen
Antwerp, Belgium · Recruiting
Cliniques Universitaires de Bruxelles - Hôpital Erasme
Brussels, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.